Actym Therapeutics is developing innovative cancer treatments. Their research centers on manipulating the tumor microenvironment (TME) to enhance the body's immune response against cancer. Actym's unique approach involves a genetically modified bacterial vehicle designed to deliver multiple therapeutic payloads directly to the tumor site. By targeting specific metabolites within the TME, this bacterial vehicle selectively accumulates in tumors, amplifying its therapeutic effect and stimulating an immune response. This novel drug modality has the potential to revolutionize cancer treatment by overcoming the challenges of the complex tumor microenvironment.

Actym Therapeutics, Inc.

Founded: 2017
Location: Berkeley, California
Employee range: 1-50
Clinical stage: Clin0
Therapy area: Oncology
Drug types: ONC
Lead product: ACTM-838
Funding: 10 - 100M

Drug notes:

About:

Jobs: